AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • November 4th, 2021 • Surface Oncology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (“Amendment No. 1”) to the License Agreement dated December 20, 2020 between GlaxoSmithKline Intellectual Property (No. 4) Limited, having a principal place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS United Kingdom (“GSK”) and Surface Oncology, Inc., having a place of business at 50 Hampshire Street, Cambridge MA 02139 (“Surface”) is effective as of August 11, 2021 (“Amendment Effective Date”). Each of GSK and Surface may be referred to herein as a “Party” and together, the “Parties”.
